The $79 Bn Boom in North America Cell and Gene Therapy Market: Trends, Challenges, and Opportunities

The North America Cell and Gene Therapy Market was valued at USD 9.19 billion in 2024, is forecasted to grow to USD 11.34 billion in 2025, and is expected to reach USD 79.01 billion by 2034, with a CAGR of 24.01% from 2025 to 2034. The market growth is attributed to the rising prevalence of chronic and rare diseases, the accelerated development of advanced therapies, and increasing regulatory support for gene and cell-based treatments.

Download the free sample and get the complete insights and forecasts report on this market @ https://www.towardshealthcare.com/download-sample/6297

Market Size (2024 – 2034)

➤2024: USD 9.19 billion

➤2025: USD 11.34 billion

➤2034 (Projected): USD 79.01 billion

➤CAGR (2025 – 2034): 24.01%

Market Trends

Rapid Growth of Oncology Treatments: Oncology continues to dominate the market, contributing to approximately 45% of the revenue in 2024. Advances in CAR-T and gene therapies targeting cancer are key drivers.

Rising Investments: Major investments in cell and gene therapies are growing, with pharmaceutical companies like Novartis, Gilead Sciences, and Bristol Myers Squibb playing pivotal roles in advancing therapies like CAR-T and gene editing.

Gene Therapy Advancements: Gene therapy is expected to grow rapidly over the forecast period due to the promise of curing genetic disorders through CRISPR and other gene-editing technologies.

Emerging Non-Viral Vectors: Non-viral vectors, particularly lipid nanoparticles (LNPs), are set to grow at the fastest rate due to their high gene-loading capacity and safety.

Increased Clinical Trials: The increase in large-scale clinical trials, particularly in gene editing technologies like CRISPR, is a significant trend.

FDA Approvals and Accelerated Pathways: The FDA’s accelerated approval processes for gene and cell therapies are boosting the market by facilitating quicker entry of innovative treatments.

Rise in Regulatory Support for Rare Diseases: Initiatives like the FDA’s Rare Disease Endpoint Advancement (RDEA) Pilot Program are accelerating drug development for rare genetic disorders.

Shift Toward Commercial-Scale Manufacturing: The growth in commercial-scale manufacturing is driven by the increasing demand for high-volume production of gene and cell therapies.

Enhanced Focus on Personalized Medicine: AI, personalized diagnostics, and gene therapies are becoming closely integrated, allowing for more effective treatments tailored to individual genetic profiles.

Strong Academic and Research Collaboration: Universities and research institutions in regions like California and Massachusetts are focusing on innovative delivery platforms and advancing gene therapies.

AI’s Impact on the North America Cell and Gene Therapy Market

Predictive Modeling: AI-driven models are being used to predict the efficacy of gene therapies before clinical trials begin, reducing development costs.

Gene Editing Precision: Machine learning (ML) algorithms are being used to improve the accuracy and precision of CRISPR gene editing technologies.

Clinical Trial Optimization: AI is optimizing the design and execution of clinical trials by analyzing patient data to select ideal candidates for trials.

Drug Repurposing: AI is helping identify existing drugs that can be repurposed for gene therapies, accelerating the therapeutic pipeline.

Automated Data Analysis: Machine learning algorithms are analyzing large datasets from clinical trials, enabling real-time decision-making in therapy development.

Personalized Medicine: AI systems are enabling the personalization of gene therapies based on a patient’s genetic makeup, enhancing treatment outcomes.

Cell Differentiation Predictions: AI models are improving predictions of stem cell differentiation, aiding in the creation of more effective cell-based therapies.

Target Identification for Gene Therapy: AI is being used to identify new genetic targets for therapeutic intervention, expanding the potential for gene therapies.

Predicting Treatment Outcomes: AI tools predict how patients will respond to different cell and gene therapies based on their genetic data.

Optimizing Manufacturing Processes: AI algorithms are being used to optimize manufacturing processes, ensuring consistent and scalable production of gene therapies.

Regional Insights: North America Cell and Gene Therapy Market

U.S. Market Insights

Dominance in Market Share

➤Expected to capture 85% of the revenue in 2024.

➤Driven by leading biotech companies and research institutions.

FDA Approvals

➤Plays a critical role in accelerating gene therapy approvals.

➤Fast-tracked approvals for CAR-T therapies and genetic disorder treatments.

Investment in Innovation

➤Home to biotech giants like Gilead Sciences, Novartis, and Moderna.

➤Focus on cutting-edge technologies like CRISPR gene editing and CAR-T therapies.

Strong Clinical Trial Ecosystem

➤Universities and research centers (e.g., Harvard, Stanford) drive advancements.

➤Large-scale trials for cancer treatments and genetic disorders.

Canada Market Insights

Government Support and Policy

➤Health Canada regulates gene therapies and supports commercialization.

➤Incentives and grants for innovative biotech companies.

Centre for Commercialisation of Regenerative Medicine (CCRM)

➤Supports academic and industry collaborations.

➤Focus on stem cell therapies and gene editing.

Biomanufacturing and Commercialization

➤OmniaBio’s new facility in Ontario boosts production capacity.

➤Expands Canada’s role in commercial-scale gene therapy manufacturing.

Research Ecosystem and Clinical Trials

➤Institutions like the Hospital for Sick Children and McGill University lead clinical trials.

➤Increasingly favorable regulatory environment for trials.

Strategic International Collaborations

➤Partnerships with U.S. companies for technology sharing and trial support.

➤OmniaBio collaborates internationally to scale gene therapy production.

Market Dynamics

Drivers

Advances in Gene and Cell Therapies

Gene Editing Technologies: Breakthroughs in CRISPR, TALENs, and ZFNs are making gene therapies more precise, enabling the treatment of previously untreatable genetic disorders.

CAR-T Therapies: The success of CAR-T therapies, particularly in blood cancers like leukemia and lymphoma, is driving market growth, with therapies like Yescarta and Kymriah leading the way.

Stem Cell Therapies: Advances in stem cell-based regenerative medicine are contributing to the development of therapies for degenerative diseases and injuries.

Regulatory Support

FDA Fast-Tracking: The FDA’s commitment to fast-tracking the approval of gene therapies, particularly for rare and life-threatening diseases, is significantly accelerating market growth.

Incentives for Rare Disease Treatments: The FDA’s Orphan Drug Designation provides regulatory support and financial incentives for the development of treatments for rare diseases, promoting innovation in the market.

Growing Prevalence of Rare Diseases

Increasing Incidence: The rising incidence of rare genetic disorders, such as sickle cell anemia, Duchenne muscular dystrophy, and hemophilia, is driving demand for specialized gene therapies.

Targeted Treatments: As the population grows and ages, there is an increasing need for targeted therapies that address the root causes of genetic disorders, making gene therapy an attractive treatment option.

Restraints

High Treatment Costs

Affordability Issues: Gene and cell therapies, particularly CAR-T and gene editing treatments, are expensive, with some therapies costing millions per patient. This high cost may limit patient access, especially in regions with limited healthcare coverage.

Reimbursement Challenges: Insurance companies and government healthcare systems may struggle to cover the costs of these therapies, hindering market penetration.

Manufacturing Complexity

Infrastructure Needs: The production of gene and cell therapies requires complex, state-of-the-art facilities and equipment. The need for highly specialized manufacturing infrastructure increases production costs.

Scale-up Challenges: Scaling gene therapies from clinical trials to large-scale commercial production presents significant challenges, particularly in terms of ensuring product consistency, quality control, and regulatory compliance.

Opportunities

Personalized Medicine

AI and Genetic Profiling: The integration of artificial intelligence (AI) with genetic profiling offers the opportunity to tailor gene therapies to individual patients based on their genetic makeup. This can lead to more effective and precise treatments, particularly for complex diseases.

Advancements in Biomarkers: The development of biomarkers to predict patient responses to specific therapies will further enhance the personalization of gene therapies, improving outcomes and minimizing side effects.

Rising Demand for Rare Disease Treatments

Regulatory and Financial Support: With increasing regulatory support, particularly in the U.S. and Europe, the market for treatments targeting rare diseases is expanding rapidly. Initiatives like the FDA’s Rare Disease Endpoint Advancement (RDEA) Pilot Program are accelerating the development of gene therapies for rare genetic conditions.

Growing Market Potential: As treatments for rare diseases are developed, the patient population is expected to grow, creating a significant market opportunity for gene therapy companies focused on rare genetic disorders.

Top 10 Companies in the North America Cell and Gene Therapy Market

1. Novartis AG

Product Line: Kymriah (CAR-T), Zolgensma (gene therapy for spinal muscular atrophy)

Overview: A global healthcare company, Novartis focuses on cell and gene therapies to treat serious diseases, including genetic disorders and blood cancers.

Strengths: Leading in CAR-T therapies and gene therapies, strong clinical pipeline.

2. Gilead Sciences (Kite Pharma)

Product Line: Yescarta, Tecartus (CAR-T therapies)

Overview: A biopharma leader in cell therapy for cancer, Gilead’s Kite Pharma has developed industry-leading CAR-T products.

Strengths: Expertise in immune-oncology therapies, strong market position.

3. Bristol Myers Squibb

Product Line: Breyanzi, Abecma (CAR-T therapies)

Overview: A global pharmaceutical company, Bristol Myers Squibb specializes in immuno-oncology and gene therapies.

Strengths: Strong oncology pipeline, leadership in cell-based therapies.

4. Bluebird Bio

Product Line: Zynteglo, Skysona (gene therapy for beta-thalassemia and adrenoleukodystrophy)

Overview: Bluebird Bio focuses on gene therapies for severe genetic diseases.

Strengths: Pioneering in gene therapies, particularly for rare diseases.

5. Spark Therapeutics (Roche)

Product Line: Luxturna (gene therapy for inherited blindness)

Overview: Acquired by Roche, Spark is a leader in gene therapies for inherited diseases.

Strengths: Market leader in gene therapies for inherited conditions.

6. CRISPR Therapeutics

Product Line: CTX001 (gene therapy for sickle cell disease and beta-thalassemia)

Overview: A leader in gene editing, CRISPR Therapeutics is at the forefront of gene therapy research.

Strengths: Strong position in CRISPR-based therapies.

7. Editas Medicine

Product Line: EDIT-101 (gene therapy for inherited retinal disease)

Overview: A pioneering biotech in gene editing, focused on developing CRISPR-based therapies.

Strengths: Innovator in gene editing technologies.

8. Intellia Therapeutics

Product Line: NTLA-2001 (gene therapy for transthyretin amyloidosis)

Overview: Focused on CRISPR-based gene therapies, Intellia is advancing treatments for genetic disorders.

Strengths: Strong expertise in CRISPR gene editing.

9. Sangamo Therapeutics

Product Line: SB-525 (gene therapy for hemophilia A)

Overview: A leader in gene therapy, particularly for genetic diseases like hemophilia.

Strengths: Expertise in gene editing and gene therapies.

10. Vertex Pharmaceuticals

Product Line: Kalydeco, Trikafta (for cystic fibrosis)

Overview: Vertex is known for its work on gene therapies for cystic fibrosis and other genetic diseases.

Strengths: Market leader in cystic fibrosis treatments, strong product pipeline.

Recent Developments

University of Rochester Collaboration (July 2025): Partnered with four other research centers in New York to advance gene and cellular therapies for cancer.

UCSF Benioff Children’s Hospital (November 2024): Launched a clinical trial using non-viral CRISPR-Cas9 gene-editing technology for sickle cell disease.

Segmentation in the North America Cell and Gene Therapy Market

1. By Therapy Type

Cell Therapy:
Cell therapy is a treatment approach that involves the transplantation or modification of living cells to treat diseases. The two primary types of cell therapy are:

Stem Cell Therapy: Involves using stem cells, which have the unique ability to differentiate into various cell types, to repair or replace damaged tissues. Stem cell therapy is particularly useful in regenerative medicine for diseases like spinal cord injuries, heart disease, and neurological disorders.

Immune Cell Therapy: This includes therapies such as CAR-T (Chimeric Antigen Receptor T-cell therapy), TCR-T (T-cell receptor therapy), and NK Cells (Natural Killer Cells):

CAR-T Therapy: Uses genetically modified T cells to attack cancer cells. It is particularly effective in treating hematological cancers like leukemia and lymphoma.

TCR-T Therapy: A newer immune cell therapy that enhances T cells to recognize cancer antigens.

NK Cell Therapy: Natural Killer cells, a type of immune cell, are expanded and modified to enhance their cancer-killing properties.

Gene Therapy:
Gene therapy involves introducing, modifying, or silencing genes within a patient’s cells to treat or cure diseases. There are several subtypes:

Gene Augmentation Therapy: Involves adding healthy copies of a gene to compensate for a defective or missing gene, often used for genetic disorders like cystic fibrosis or Duchenne muscular dystrophy.

Gene Editing (CRISPR, TALENs, ZFNs): This involves directly editing the genes in the patient’s cells. CRISPR is the most widely used, allowing for precise cutting and modification of DNA.

CRISPR: A revolutionary gene-editing technology that can target specific DNA sequences and modify them with high precision.

TALENs (Transcription Activator-Like Effector Nucleases) and ZFNs (Zinc Finger Nucleases): These are other forms of gene-editing technologies, though less widely used than CRISPR.

RNA-based Therapies: RNA therapies like siRNA (small interfering RNA), mRNA (messenger RNA), and Antisense oligonucleotides are designed to modify or silence genes at the RNA level, helping treat diseases like genetic disorders or viral infections.

2. By Therapeutic Area

Oncology:

Dominance: Oncology is the largest segment in the North America cell and gene therapy market, holding approximately 45% of the total market share in 2024. The demand for advanced cancer therapies, particularly for blood cancers, is driving this dominance.

Growth Drivers: The ongoing advancements in CAR-T cell therapy, gene-editing technologies like CRISPR, and RNA-based therapies have significantly improved the effectiveness of cancer treatment, leading to rapid adoption in the oncology field.

Market Impact: CAR-T therapies, such as Gilead’s Yescarta and Bristol Myers Squibb’s Breyanzi, are contributing to the market’s growth, as they offer long-lasting remission in patients with difficult-to-treat cancers.

Rare Genetic Disorders:

Fastest Growth: The rare genetic disorder segment is expected to grow at the fastest rate during the forecast period (2025-2034).

Demand Drivers: Advancements in gene therapy, particularly CRISPR, offer the potential for permanent cures for diseases like sickle cell anemia, Duchenne muscular dystrophy, and hemophilia.

Regulatory Support: The FDA’s Orphan Drug Designation and support for gene therapy treatments for rare diseases have encouraged increased investment and research in this area, leading to rapid market growth.

3. By Vector Type

Viral Vectors:

Dominance: Viral vectors are the most commonly used delivery systems for gene therapy, accounting for approximately 70% of the market share in 2024.

Types:

Adeno-Associated Virus (AAV): Commonly used due to its non-pathogenic nature and ability to transfect both dividing and non-dividing cells, making it ideal for therapies targeting tissues like the eye, liver, and muscle.

Lentivirus: Used for introducing genes into dividing and non-dividing cells, especially in hematological diseases like leukemia, making it a common vector for CAR-T therapies.

Retrovirus: Used in gene therapy targeting hematopoietic cells (blood stem cells), especially in the treatment of genetic disorders such as sickle cell anemia.

Adenovirus: Although effective, they are more transient and may provoke immune responses, limiting their long-term use.

Non-Viral Vectors:

Emerging Growth: Non-viral vectors are expected to grow at the fastest rate during 2025-2034.

Advantages: Non-viral vectors, like lipid nanoparticles (LNPs) and electroporation, offer significant safety advantages over viral vectors.

Lipid Nanoparticles (LNPs): These particles are used for delivering mRNA, siRNA, and DNA into cells. LNPs are known for their high gene-loading capacity and ease of manufacture.

Electroporation: A method that uses electrical fields to enhance the delivery of genetic material into cells, ideal for ex vivo gene therapies like CAR-T.

4. By Cell Source

Autologous:

Dominance: The autologous segment dominated the market in 2024, accounting for 60% of the market share.

Benefits: Autologous cell therapy uses a patient’s own cells, minimizing the risk of immune rejection and enhancing the potential for long-term therapeutic effects.

Applications: Used in stem cell therapies and CAR-T therapies, where a patient’s T cells are extracted, modified, and reinfused to treat cancers or autoimmune diseases.

Allogeneic:

Fastest Growth: The allogeneic segment is expected to grow at the fastest rate from 2025-2034.

Advantages: Allogeneic therapies use cells from a healthy donor, allowing for “off-the-shelf” treatments that can be stored and readily used for multiple patients.

Applications: Potentially transformative for scaling CAR-T therapies, as it allows for mass production of treatments.

5. By Manufacturing Scale

Clinical-Scale Manufacturing:

Dominance: Clinical-scale manufacturing dominated the North America cell and gene therapy market in 2024, accounting for approximately 65% of the revenue.

Purpose: Clinical-scale manufacturing is used to produce sufficient quantities of gene and cell therapies for clinical trials. This step bridges the gap between lab research and large-scale commercial production.

Challenges: Ensuring the consistent quality and safety of cell and gene therapies in clinical trials requires highly controlled and scalable manufacturing processes.

Commercial-Scale Manufacturing:

Fastest Growth: The commercial-scale manufacturing segment is expected to grow at the fastest rate from 2025-2034.

Growth Drivers: As gene and cell therapies gain FDA approvals and move toward widespread use, commercial-scale manufacturing is essential to meet growing demand. Scaling up production requires more advanced, cost-efficient technologies and processes.

Challenges: Commercial-scale manufacturing faces challenges related to quality control, cost reduction, and meeting regulatory standards.

Top 5 FAQs

1. What is gene therapy?
   Gene therapy involves modifying or replacing defective genes to treat genetic diseases.

2. Which segment is growing the fastest in this market?
   The gene therapy segment, especially gene editing therapies, is expected to grow the fastest.

3. What are viral and non-viral vectors in gene therapy?
   Viral vectors are modified viruses used to deliver genetic material, while non-viral vectors, such as lipid nanoparticles, offer safer and more efficient alternatives.

4. What are the main challenges in the cell and gene therapy market?
   High treatment costs, manufacturing complexities, and regulatory hurdles are the main challenges.

5. Which companies are leading the North American market?
   Novartis, Gilead Sciences (Kite Pharma), and Bristol Myers Squibb are leading companies in the market.